|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||31.37 - 31.55|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||21.60|
|Dividend & Yield||1.03 (3.30%)|
|1y Target Est||N/A|
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
Diabetes accounts for nearly 10% of US health care spending
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.